Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene study may unlock secrets of allergies and asthma

NCT ID NCT01678222

Knowledge-focused Sponsor: National Institute of Environmental Health Sciences (NIEHS) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 02, 2026 · Updated 14 times

Summary

This study looked at how small differences in the COX-2 gene affect the balance of immune cells that play a role in allergies and asthma. Researchers analyzed blood and urine samples from 117 adults who were part of a larger genetic registry. No treatments were given; the goal was simply to understand how these gene variations influence immune responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

117 people

The number who actually took part.

Started

May 2013

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

individuals who are homozygous for either the major or minor variant of both SNPs@@@

Ages

18 to 150 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Participant of the Environmental Polymorphisms Registry and current contact information available * Genotype information available for relevant 765G\>C and 8473T\>C COX2 polymorphisms, which indicates: * Individuals who are WT with respect to both 765G\>C and 8473T\>C (N=31) * Individuals who are WT with respect to 765G\>C and homozygous for 8473T\>C (N=31) * Individuals who are homozygous for both 765G\>C and 8473T\>C (N=31) * Age 18- 65 years * Race self-identified as White or Black and Non-Hispanic ethnicity * Willing and able to provide informed consent * Able to comply with all protocol procedures EXCLUSION CRITERIA: * History of infection within the preceding 1 week or an oral temperature \>38 degrees C * Current daily or chronic use of corticosteroids (systemic, inhaled and topical). * Any current conditions known to impact peripheral white blood cell count (e.g., leukemia, lymphopenia, AIDS, other immunodeficiency disorders) * Current daily or chronic use of systemic immunosuppressants. * Current pregnancy or lactation * Unwilling or unable to: * Fast (including alcohol and caffeine-containing products) and discontinue tobacco use for 12 hours prior to the study visit * Withhold all prescribed and over-the-counter medications and supplements the morning of the study visit, until after the visit is completed * Refrain from taking the following medications and supplements for 7 days prior to the study visit: * NSAIDs * Corticosteroids (nasal, inhaled, topical or systemic) * Fish oil and niacin supplements * For blood draws that exceed 200ml, a hematocrit of \<34% for women or \<36% for men, or \>56% for either gender. * For blood draws exceeding 200ml, blood or plasma donation in the last 8 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic inflammation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic inflammation Asthma

Contacts and locations

Locations

  • NIEHS Clinical Research Unit (CRU)

    Research Triangle Park, North Carolina, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.